

What is claimed is:

1. An oligonucleotide formulation suitable for rectal delivery.
2. The formulation of claim 1, wherein said formulation is an enema.
3. The formulation of claim 1, wherein said formulation is a suppository.
4. The formulation of claim 2, wherein said enema comprises an oligonucleotide solution.
5. The formulation of claim 2, wherein said enema comprises an oligonucleotide emulsion.
6. The formulation of claim 4, wherein said solution is a saline solution.
7. The formulation of claim 4, wherein said solution is a buffered solution.
8. The formulation of claim 1, wherein said oligonucleotide is an antisense oligonucleotide.
9. The formulation of claim 8, wherein said antisense oligonucleotide modulates expression of a cellular adhesion protein.
10. The formulation of claim 8, wherein said antisense oligonucleotide modulates a rate of cellular proliferation or has biological activity against eukaryotic pathogens or retroviruses.
11. The formulation of claim 9, wherein said cellular adhesion protein is ICAM-1.
12. The formulation of claim 1 wherein said antisense oligonucleotide has the sequence shown in SEQ ID NO: 1 (ISIS 2302).
13. The formulation of claim 1, wherein said enema comprises an emulsion.
14. The formulation of claim 1, further comprising at least one penetration enhancer.

15. The formulation of claim 14, wherein said penetration enhancer is a fatty acid, bile salt, chelating agent, surfactant or non-chelating non-surfactant.
16. A method of treating an animal having an inflammatory bowel disorder comprising administering to said animal a therapeutically effective amount of an oligonucleotide formulation suitable for rectal delivery.
17. The method of claim 16, wherein said animal is a human.
18. The method of claim 16, wherein said inflammatory bowel disorder is ulcerative colitis.
19. The method of claim 16, wherein said inflammatory bowel disorder is Crohn's disease or inflammatory bowel disease.
20. The method of claim 16, wherein said oligonucleotide is an antisense oligonucleotide.
21. The method of claim 16, wherein said formulation is an enema.
22. The method of claim 16, wherein said formulation is a suppository.
23. The method of claim 20, wherein said antisense oligonucleotide modulates expression of a cellular adhesion protein.
24. The method of claim 20, wherein said antisense oligonucleotide modulates a rate of cellular proliferation or has biological activity against eukaryotic pathogens or retroviruses.
25. The method of claim 23, wherein said cellular adhesion protein is ICAM-1.
26. The method of claim 25, wherein said oligonucleotide has the sequence shown in SEQ ID NO: 1.